Document is current
Any future updates will be listed below
-
Authors
Li, Zhijian https://orcid.org/0000-0003-1849-1672
Ee, Aloysius
Amaya, Laura https://orcid.org/0000-0002-8742-9111
Hamad, Jennifer L. https://orcid.org/0000-0002-0806-6835
Yadav, Pavan K.
Wang, Sean K. https://orcid.org/0000-0003-1557-8510
Chang, Howard Y. https://orcid.org/0000-0002-9459-4393
Wender, Paul A. https://orcid.org/0000-0001-6319-2829
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA245533)
- License Information
-
More Information
Article History
Received: 19 December 2024
Accepted: 16 July 2025
First Online: 1 August 2025
Competing interests
: H.Y.C. is an employee and stockholder of Amgen as of Dec. 16, 2024. H.Y.C. is a co-founder of Accent Therapeutics, Boundless Bio, Cartography Biosciences, Orbital Therapeutics, and until Dec. 15, 2024, an advisor of Arsenal Biosciences, Chroma Medicine, Exai Bio, and Spring Science. P.A.W. is a co-founder of BryoLogyx and N1 Life and an advisor to Vaxanix, N1 Life, Synaptogenix, Cytokinetics, SuperTrans Medical, Ativo and Vault Pharma. The remaining authors declare no competing interests.
